三剂疫苗接种可引发针对奥密克戎的中和抗体。 - Suppr

Three-dose vaccination elicits neutralising antibodies against omicron.

作者信息

Wu Mary, Wall Emma C, Carr Edward J, Harvey Ruth, Townsley Hermaleigh, Mears Harriet V, Adams Lorin, Kjaer Svend, Kelly Gavin, Warchal Scott, Sawyer Chelsea, Kavanagh Caitlin, Queval Christophe J, Ngai Yenting, Hatipoglu Emine, Ambrose Karen, Hindmarsh Steve, Beale Rupert, Gamblin Steve, Howell Michael, Kassiotis George, Libri Vincenzo, Williams Bryan, Gandhi Sonia, Swanton Charles, Bauer David Lv

机构信息

The Francis Crick Institute, London NW1 1AT, UK.

The Francis Crick Institute, London NW1 1AT, UK; National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, London, UK.

出版信息

Lancet. 2022 Feb 19;399(10326):715-717. doi: 10.1016/S0140-6736(22)00092-7. Epub 2022 Jan 19.

DOI:10.1016/S0140-6736(22)00092-7

PMID:35065005

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8769665/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0b5/8769665/3c1760230f0b/fx1_lrg.jpg

相似文献

Three-dose vaccination elicits neutralising antibodies against omicron.三剂疫苗接种可引发针对奥密克戎的中和抗体。

Lancet. 2022 Feb 19;399(10326):715-717. doi: 10.1016/S0140-6736(22)00092-7. Epub 2022 Jan 19.

Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost.奥密克戎变异株对疫苗加强后免疫血清的中和敏感性低于其他 SARS-CoV-2 变异株。

Emerg Microbes Infect. 2022 Dec;11(1):337-343. doi: 10.1080/22221751.2021.2022440.

BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.BNT162b2 新冠病毒疫苗与体液免疫应答及动力学的相关性：医护人员前瞻性、单中心、纵向队列研究。

Lancet Respir Med. 2021 Sep;9(9):999-1009. doi: 10.1016/S2213-2600(21)00220-4. Epub 2021 Jul 2.

Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?接受BNT162b2 mRNA疫苗或AZD1222疫苗的健康志愿者中针对SARS-CoV-2的中和抗体反应比较：AZD1222疫苗的第二剂是否应提前接种？

Am J Hematol. 2021 Sep 1;96(9):E321-E324. doi: 10.1002/ajh.26248. Epub 2021 Jun 2.

Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial.二价（奥密克戎 BA.5 加原始株）SARS-CoV-2 重组刺突蛋白疫苗作为异源加强针的免疫原性和安全性：一项 3 期、非劣效性、随机、临床试验的中期分析。

Lancet Infect Dis. 2024 Jun;24(6):581-593. doi: 10.1016/S1473-3099(24)00077-X. Epub 2024 Mar 6.

XBB.1.5 monovalent vaccine induces lasting cross-reactive responses to SARS-CoV-2 variants such as HV.1 and JN.1, as well as SARS-CoV-1, but elicits limited XBB.1.5 specific antibodies.XBB.1.5单价疫苗可诱导对SARS-CoV-2变体（如HV.1和JN.1）以及SARS-CoV-1产生持久的交叉反应，但产生的XBB.1.5特异性抗体有限。

mBio. 2025 Apr 9;16(4):e0360724. doi: 10.1128/mbio.03607-24. Epub 2025 Mar 5.

Estimating neutralising antibody responses against emerging SARS-CoV-2 variants utilising convalescent sera before the roll-out of XBB-lineage vaccines.在XBB谱系疫苗推出之前，利用康复期血清评估针对新出现的SARS-CoV-2变体的中和抗体反应。

Vaccine. 2025 Apr 2;51:126898. doi: 10.1016/j.vaccine.2025.126898. Epub 2025 Feb 20.

The long road.漫长的道路。

Science. 2021 Feb 19;371(6531):768-772. doi: 10.1126/science.371.6531.768.

Neutralizing SARS-CoV-2.中和 SARS-CoV-2

Elife. 2020 Dec 15;9:e64496. doi: 10.7554/eLife.64496.

Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac.科兴新冠疫苗诱导产生的针对新冠病毒变异株的血清中和活性。

Lancet Infect Dis. 2021 Aug;21(8):1071-1072. doi: 10.1016/S1473-3099(21)00287-5. Epub 2021 May 27.

引用本文的文献

SARS-CoV-2 antibody immunity across three continents: the West Africa, West Indies, West London Consortium.三大洲的新型冠状病毒2型抗体免疫情况：西非、西印度群岛、西伦敦联盟

medRxiv. 2025 Jun 14:2025.06.13.25329588. doi: 10.1101/2025.06.13.25329588.

Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study.加纳成年人在完成新冠疫苗基础免疫后产生的中和抗体滴度高于且比英国匹配的成年人更持久：HERITAGE研究。

BMC Med. 2025 May 28;23(1):312. doi: 10.1186/s12916-025-04157-0.

Recent approaches in computational modelling for controlling pathogen threats.近期用于控制病原体威胁的计算建模方法。

Life Sci Alliance. 2024 Jun 21;7(9). doi: 10.26508/lsa.202402666. Print 2024 Sep.

A Longitudinal Study in Tunisia to Assess the Anti-RBD IgG and IgA Responses Induced by Three Different COVID-19 Vaccine Platforms.突尼斯的一项纵向研究，以评估三种不同新冠疫苗平台诱导的抗受体结合域免疫球蛋白G和免疫球蛋白A反应。

Trop Med Infect Dis. 2024 Mar 13;9(3):61. doi: 10.3390/tropicalmed9030061.

COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.4/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history.非住院的成年人感染 SARS-CoV-2 亚变体奥密克戎 BA.1、BA.2、BA.4/5 或德尔塔导致的 COVID-19，无论其疫苗接种史如何，其疾病持续时间、症状严重程度和病毒动力学均相似。

PLoS One. 2024 Mar 21;19(3):e0294897. doi: 10.1371/journal.pone.0294897. eCollection 2024.

A Comparison Between Omicron and Earlier COVID-19 Variants' Disease Severity in the Milan Area, Italy.意大利米兰地区奥密克戎毒株与早期新冠病毒变体疾病严重程度的比较

Front Epidemiol. 2022 Jun 28;2:891162. doi: 10.3389/fepid.2022.891162. eCollection 2022.

Combined analyses of within-host SARS-CoV-2 viral kinetics and information on past exposures to the virus in a human cohort identifies intrinsic differences of Omicron and Delta variants.对人类队列中个体内 SARS-CoV-2 病毒动力学和既往病毒暴露信息的联合分析，鉴定出了奥密克戎和德尔塔变异株的内在差异。

PLoS Biol. 2024 Jan 30;22(1):e3002463. doi: 10.1371/journal.pbio.3002463. eCollection 2024 Jan.

Humoral responses to wild type and ancient BA.1 SARS-CoV-2 variant after heterologous priming vaccination with ChAdOx1 nCoV-19 and BNT162b2 booster dose.异源加强接种 ChAdOx1 nCoV-19 和 BNT162b2 后对野生型和古老 BA.1 SARS-CoV-2 变异株的体液反应。

Clin Exp Med. 2024 Jan 20;24(1):12. doi: 10.1007/s10238-023-01276-x.

The 6-Month Antibody Durability of Heterologous Convidecia Plus CoronaVac and Homologous CoronaVac Immunizations in People Aged 18-59 Years and over 60 Years Based on Two Randomized Controlled Trials in China.基于中国两项随机对照试验的18-59岁及60岁以上人群中异源康希诺生物新冠疫苗加强针加科兴新冠疫苗和同源科兴新冠疫苗接种的6个月抗体持久性研究

Vaccines (Basel). 2023 Dec 4;11(12):1815. doi: 10.3390/vaccines11121815.

A population-based and symptom-based COVID-19 prevalence survey.一项基于人群和症状的新冠病毒感染率调查。

J Educ Health Promot. 2023 Jul 29;12:260. doi: 10.4103/jehp.jehp_1554_22. eCollection 2023.

本文引用的文献

Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer.与实体癌患者相比，血液系统恶性肿瘤患者在第三次接种新冠疫苗后的免疫反应有所降低。

Cancer Cell. 2022 Apr 11;40(4):438. doi: 10.1016/j.ccell.2022.03.010.

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.卡司瑞韦单抗和伊德韦单抗联合治疗住院 COVID-19 患者（RECOVERY）：一项随机、对照、开放标签、平台试验。

Lancet. 2022 Feb 12;399(10325):665-676. doi: 10.1016/S0140-6736(22)00163-5.

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.奥密克戎对抗体中和作用的逃逸显著。

Nature. 2022 Feb;602(7898):671-675. doi: 10.1038/s41586-021-04389-z. Epub 2021 Dec 23.

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization.奥密克戎能广泛但不完全地逃避辉瑞 BNT162b2 的中和作用。

Nature. 2022 Feb;602(7898):654-656. doi: 10.1038/s41586-021-04387-1. Epub 2021 Dec 23.

Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil.两剂 ChAdOx1 nCoV-19 疫苗对 COVID-19 住院和死亡的保护作用随时间变化的回顾性、基于人群的队列研究：苏格兰和巴西的研究。

Lancet. 2022 Jan 1;399(10319):25-35. doi: 10.1016/S0140-6736(21)02754-9. Epub 2021 Dec 20.

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum.免疫后血清对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎B.1.1.529变体的中和作用降低。

Lancet. 2022 Jan 15;399(10321):234-236. doi: 10.1016/S0140-6736(21)02844-0. Epub 2021 Dec 20.

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis.中和抗体滴度作为预测对 SARS-CoV-2 变异体的保护作用以及加强免疫的影响的指标：一项荟萃分析。

Lancet Microbe. 2022 Jan;3(1):e52-e61. doi: 10.1016/S2666-5247(21)00267-6. Epub 2021 Nov 15.

Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients.英国血液透析患者新冠病毒疫苗接种后的中和抗体

Lancet. 2021 Sep 18;398(10305):1038-1041. doi: 10.1016/S0140-6736(21)01854-7. Epub 2021 Aug 13.

Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains.与原始 SARS-CoV-2 株相比，感染 B.1.1.7 后抗体交叉反应性降低。

Elife. 2021 Jul 29;10:e69317. doi: 10.7554/eLife.69317.

AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC.AZD1222诱导的针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）Delta变异株的中和抗体活性。

Lancet. 2021 Jul 17;398(10296):207-209. doi: 10.1016/S0140-6736(21)01462-8. Epub 2021 Jun 28.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Three-dose vaccination elicits neutralising antibodies against omicron.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献